Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 29:9:54.
doi: 10.21037/tgh-24-48. eCollection 2024.

KRAS G12C inhibitors in metastatic colorectal cancer: a tale of two targets

Julia Martínez-Pérez  1   2 , Manuel Valladares-Ayerbes  1   2
Affiliations
Editorial

KRAS G12C inhibitors in metastatic colorectal cancer: a tale of two targets

Julia Martínez-Pérez et al. Transl Gastroenterol Hepatol. .
No abstract available

Keywords: KRAS G12C; Metastatic colorectal cancer (mCRC); RAS-mutant; epidermal growth factor receptor (EGFR); target therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-24-48/coif). J.M.P. received honoraria and support for attending meetings and travel from Bristol-Myers Squibb, Merck Sharp & Dohme Corp, and Merck. M.V.A. received contracts from AMGEN (Research contract, personal fees) and ROCHE (Research contract, Institutional); consulting fees from AMGEN, SERVIER, and SANOFI; payment from MSD, Bristol-Myers, and Merck; support for attending meetings and travel from Merck, SERVIER, and AMGEN; and is the member on Advisory Board from AMGEN, SERVIER, and MERCK. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 2019;575:217-23. 10.1038/s41586-019-1694-1 - DOI - PubMed
    1. Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020;383:1207-17. 10.1056/NEJMoa1917239 - DOI - PMC - PubMed
    1. Fakih M, Tu H, Hsu H, et al. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer. Oncologist 2022;27:663-74. 10.1093/oncolo/oyac077 - DOI - PMC - PubMed
    1. Henry JT, Coker O, Chowdhury S, et al. Comprehensive Clinical and Molecular Characterization of KRAS (G12C)-Mutant Colorectal Cancer. JCO Precis Oncol 2021;5:PO.20.00256. - PMC - PubMed
    1. Osterlund E, Ristimäki A, Kytölä S, et al. KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer. Front Oncol 2022;12:826073. 10.3389/fonc.2022.826073 - DOI - PMC - PubMed

LinkOut - more resources